Does Lipitor Interact with Hepatitis C Drugs?
Lipitor (atorvastatin), a statin for lowering cholesterol, has documented interactions with several hepatitis C direct-acting antivirals (DAAs). These can raise atorvastatin blood levels, increasing myopathy and rhabdomyolysis risk—muscle breakdown that may damage kidneys.[1] The FDA labels for both Lipitor and key DAAs warn of this.[2][3]
Key Interactions by Hepatitis C Medication
- With glecaprevir/pibrentasvir (Mavyret): Contraindicated. Atorvastatin levels increase up to 8-fold; avoid entirely.[2]
- With ledipasvir/sofosbuvir (Harvoni): Limit atorvastatin to 20 mg daily max. Levels rise 2.3-fold.[3]
- With daclatasvir (Daklinza): Limit to 20 mg daily. Interaction boosts exposure moderately.[4]
- With elbasvir/grazoprevir (Zepatier): Avoid atorvastatin; alternatives like pravastatin or rosuvastatin preferred at low doses.[5]
- With sofosbuvir/velpatasvir (Epclusa): Limit to 20 mg daily. CYP3A inhibition drives the rise.[6]
- Other DAAs (e.g., grazoprevir, voxilaprevir): Generally avoid statins metabolized by CYP3A4 like atorvastatin; pitavastatin or fluvastatin safer.[1]
No major issues reported with ribavirin or older interferon regimens, but DAAs dominate current treatment.
What Side Effects or Risks to Watch For
Elevated atorvastatin from interactions heightens:
- Muscle pain, weakness, or cramps (myalgia/myopathy).
- Rare but severe rhabdomyolysis, with dark urine, fatigue, or kidney failure.
- Liver enzyme elevations, risky in hepatitis C patients with existing damage.
Monitor CK levels, liver function, and symptoms closely. Start low doses if using together; switch statins if possible.[1][7]
Safer Alternatives for Cholesterol Control
- Preferred statins: Pravastatin, rosuvastatin (lower doses), or pitavastatin—less CYP3A4 dependent.
- Non-statin options: Ezetimibe, PCSK9 inhibitors (e.g., Repatha), or bempedoic acid.
- Consult a doctor for personalized switches, especially with cirrhosis.[7]
When to Talk to Your Doctor
Interactions vary by DAA regimen, liver status, and dose. Get clearance before combining; may need dose cuts, monitoring, or statin pause during hep C treatment (typically 8-12 weeks).[1] No broad patent issues affect availability—Lipitor generics are widespread.[8]
Sources
[1]: FDA Drug Interactions Table
[2]: Mavyret Prescribing Information
[3]: Harvoni Prescribing Information
[4]: Daklinza Prescribing Information
[5]: Zepatier Prescribing Information
[6]: Epclusa Prescribing Information
[7]: Hepatitis C Online - Statin Interactions
[8]: DrugPatentWatch - Atorvastatin